Deplorable to overreact, entice fear without due diligence on vax: Vardhan

The health minister also referred to an earlier tweet by him on January 15, wherein he had posted a chart with details of all those people who should not get the vaccine Read more at: https://www.dec

Harsh Vardhan
Photo: PTI
Press Trust of India New Delhi
2 min read Last Updated : Jan 19 2021 | 10:28 PM IST

It is highly deplorable to overreact, entice fear and spread misinformation without doing any due diligence on COVID-19 vaccine, Union Health Minister Harsh Vardhan said on Tuesday after Bharat Biotech released a factsheet specifying conditions when Covaxin should not be given.

He was replying to a tweet that asked why such a crucial information was allegedly not made public earlier.

The health minister also referred to an earlier tweet by him on January 15, wherein he had posted a chart with details of all those people who should not get the vaccine.

"Highly deplorable to over-react, entice fear and spread misinformation without performing an iota of due diligence. These facts have been in public domain since the beginning. Follow @MoHFW_INDIA (health ministry Twitter handel) to stay informed and do some research before speaking out," Vardhan tweeted.

In the factsheet on COVID-19 vaccine Covaxin, Bharat Biotech has advised pregnant or breastfeeding women and people with high fever or bleeding disorders not to take the antidote.

The vaccine maker in the fact sheet on Covaxin, posted in its website, said the clinical efficacy of the vaccine is yet to be established and is being studied in phase three clinical trial, and hence it is important to appreciate that receiving the vaccine does not mean other precautions related to COVID-19 need not be followed.

Covaxin has been granted approval for restricted use in emergency situations.

It is India's totally indigenous COVID-19 vaccine developed in collaboration with the Indian Council of Medical Research and the National Institute of Virology.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Harsh VardhanCoronavirus VaccineBharat Biotech

First Published: Jan 19 2021 | 10:19 PM IST

Next Story